Clinical Trial

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

Study acronym: PERFECT-AMI
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-01-28; most recent amendment 2025-05-16.
Status change: Not Yet Recruiting → Recruiting 2021-02-04
Trial Details
NCT Number NCT04731155
Lead Sponsor Shanghai Tong Ren Hospital
Conditions Early PCSK9 Inhibitor on Ventricular Remodling
Enrollment 20 participants
Start Date 2021-04-12
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-05-21